| Weight (kg) | 7 | 8.5 | 9.2 | 10.5 | 11.2 | 11.5 |
| Height (cm) | 66 | 69 | 72 | 77 | 82 | 85 |
| MCV (fl) | 92 | 92 | 92 | 92 | 92 | 92 |
| CD4 (10^3/μl) | 450 | 388 | 650 | 500 | 190 | 192 |
| P24 antigen (pg/ml) | 356 | 386 | 0 | 0 | 0 | 0 |

| Platelets (10^9/l) | 10 | 280 | 10 | 390 | 480 | 380 | 10 | 290 | 10 | 350 | 450 | 350 | 350 |
| **Route of zidovudine** | Oral | CI | Oral | Oral | CI |
| **Age (months)** | 12 | 19 | 22 | 25 | 33 | 36 |

Patient’s data covering a period of 20 months, starting at 12 months of age when thrombocytopenia developed; CI = continuous infusion, MCV = mean corpuscular volume.

anaemia. On two occasions (at 22 and 25 months of age) the intravenous route was transiently switched to oral treatment at a daily dose of 600 mg/m² (24 mg/kg) given in four or six divided doses. Each time a symptomatic relapse occurred and was corrected when the intravenous route was resumed. Plasma concentrations of zidovudine were measured by high performance liquid chromatography. At 150 mg/m²/6 hours (24 mg/kg/day) given orally, the peak plasma concentration one hour after oral dosing was 800 ng/ml and the trough level was undetectable (limit of detection: 12.5 ng/ml); these levels were similar to those determined in our other HIV positive children, excluding a specific defect of zidovudine absorption in our patient. Steady state concentration was 534 ng/ml during continuous infusion.

The low rate derived from BPSU reports may be due to the fact that paediatricians did not link the illness (which was usually mild) to mesails, mumps, rubella vaccination, which had been given up to 28 days previously. This could be avoided by taking a full immunisation history (including dates) on all children at the time of admission. Particular attention should be paid to vaccinations in the previous month.

<table>
<thead>
<tr>
<th>Patient’s data covering a period of 20 months, starting at 12 months of age when thrombocytopenia developed; CI = continuous infusion, MCV = mean corpuscular volume.</th>
<th><strong>Route of zidovudine</strong></th>
<th>Oral</th>
<th>CI</th>
<th>Oral</th>
<th>Oral</th>
<th>CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (months)</strong></td>
<td>12</td>
<td>19</td>
<td>22</td>
<td>25</td>
<td>33</td>
<td>36</td>
</tr>
</tbody>
</table>

Haemorrhagic shock encephalopathy or near miss sudden infant death syndrome?

**EDITOR,—DrS Bacon and Hall suggest that haemorrhagic shock encephalopathy syndrome (HSES) is probably a secondary phenomenon after a severe initial insult.** We hypothesise that this syndrome may represent the result of acute onset, severe hypoaemia as may occur in infants who suffer apparent life threatening events (ALTE). Many of the features of HSES are similar to those that occur in infants who have suffered ALTE or sudden infant death syndrome (SIDS): median age of 15 weeks, peak onset period at night, slight excess in winter months, mild prodomal illness, found hot and sweaty, and with postmortem pulmonary congestion.

Previous reports on changes after severe ‘near miss’ SIDS have also shown the presence of metabolic acidosis, cardiovascular instability, acute renal failure, ischaemic colitis and acute neurological dysfunction. Some of these infants also showed mild hepatic cellular dysfunction and hyponatraemia. It may be appropriate for infants who have recovered from HSES to be screened for abnormalities in oxygenation. However, as with SIDS, the dilemma is to identify patients at risk of this life threatening illness before symptoms develop.

**Martin Samuels**

**Academic Department of Paediatrics,**

**University of Keele,**

**North Staffordshire Hospital Centre,**

**Stoke on Trent**

**6QG**

| **Treatment of refractory ulcerative oesophagitis with omeprazole** | **EDITOR,—We read the paper of Dalzell et al with interest. They reported a complete resolution of ulcerative oesophagitis refractory to H2 blockers by omeprazole in a 7 year old boy. We recently saw a 4 month old boy who was diagnosed endoscopically to have an ulcerative oesophagitis at the age of 2 months. A two month course of cispamide, cimetidine, and a mucosal protective agent (alginate antacid), together with thickening of the feeds and positioning initially improved his symptoms of crying when drinking milk. While still taking this treatment, however, excessive crying during and after milk feedings recurred. Urine analysis was normal. A semi-solid diet had already been introduced without obvious benefit. Endoscopy revealed a marked distal oesotitis. Omeprazole at 3.5 mg (0.5 mg/kg) once a day was given for a period of six weeks. During the first 48 hours of this treatment, the clinical symptoms disappeared spectacularly. Endoscopy five weeks later did not reveal any signs of oesophagitis.** | **Cherif Rahmy**

**Evelyne Jacoz-Agrain**

**Anne Broyard**

**Francoise Brun-Vezinet**

**Etienne Vilmer**

**Departments of Haematology-Immunology and Clinical Pharmacology, Hôpital Robert Debré, 48 Boulevard Servien, 75019 Paris, France.**


---Reporting of vaccine associated mumps meningitis

**EDITOR,—Vaccine associated mumps meningitis was one of the conditions reportable to the British Paediatric Surveillance Unit (BPSU) between February 1990 and January 1992. During this two year period, 15 confirmed cases were reported. Eight reports were in children aged 12-24 months resident in England and Wales. Based on the BPSU study the estimated risk of vaccine associated mumps meningitis in this age group was 1:5 per 100 000 vaccinations given. However when the BPSU data were supplemented by laboratory reports, a much higher rate of approximately 10 per 100 000 vaccinations was observed (Dr E Miller, personal communication). This higher rate is consistent with observations in other countries.'

---Haemorrhagic shock encephalopathy or near miss sudden infant death syndrome?

**EDITOR,—DrS Bacon and Hall suggest that haemorrhagic shock encephalopathy syndrome (HSES) is probably a secondary phenomenon after a severe initial insult.** We hypothesise that this syndrome may represent the result of acute onset, severe hypoaemia as may occur in infants who suffer apparent life threatening events (ALTE). Many of the features of HSES are similar to those that occur in infants who have suffered ALTE or sudden infant death syndrome (SIDS): median age of 15 weeks, peak onset period at night, slight excess in winter months, mild prodomal illness, found hot and sweaty, and with postmortem pulmonary congestion.

Previous reports on changes after severe ‘near miss’ SIDS have also shown the presence of metabolic acidosis, cardiovascular instability, acute renal failure, ischaemic colitis and acute neurological dysfunction. Some of these infants also showed mild hepatic cellular dysfunction and hyponatraemia. It may be appropriate for infants who have recovered from HSES to be screened for abnormalities in oxygenation. However, as with SIDS, the dilemma is to identify patients at risk of this life threatening illness before symptoms develop.

**Martin Samuels**

**Academic Department of Paediatrics,**

**University of Keele,**

**North Staffordshire Hospital Centre,**

**Stoke on Trent**

**6QG**

---Treatment of refractory ulcerative oesophagitis with omeprazole

**EDITOR,—We read the paper of Dalzell et al with interest. They reported a complete resolution of ulcerative oesophagitis refractory to H2 blockers by omeprazole in a 7 year old boy. We recently saw a 4 month old boy who was diagnosed endoscopically to have an ulcerative oesophagitis at the age of 2 months. A two month course of cispamide, cimetidine, and a mucosal protective agent (alginate antacid), together with thickening of the feeds and positioning initially improved his symptoms of crying when drinking milk. While still taking this treatment, however, excessive crying during and after milk feedings recurred. Urine analysis was normal. A semi-solid diet had already been introduced without obvious benefit. Endoscopy revealed a marked distal oesotitis. Omeprazole at 3.5 mg (0.5 mg/kg) once a day was given for a period of six weeks. During the first 48 hours of this treatment, the clinical symptoms disappeared spectacularly. Endoscopy five weeks later did not reveal any signs of oesophagitis.**

**Philippe Alliet**

**Marc Raes**

**Philippe Gillis**

**Mieke Calleraert**

**Andre Zimmermann**

**Vega Jesse Hospital,**

**Department of Paediatrics,**

**Santoméarea 11,**

**B-3500, Guilla, Belgium.**


---Cox NH. Acute disseminated epidermal necrosis due to omeprazole. Lancet 1992; 340: 1071.'


---Recurrent parotitis

**EDITOR,—We were interested to read that the cause of recurrent parotitis in children 'has of yet not been satisfactorily explained.'

---
Over 10 years ago we were able, in six consecutive cases, to demonstrate a deficiency in salivary (secretory) IgA. This deficiency did not relate necessarily to low serum IgA concentrations. In these cases sialectasis was not demonstrated and, indeed, appears to be very rare in early well treated disease. It appears to be secondary to recurrent infection. The last child we saw who required parotidectomy was seen in 1960.

In our practice recurrent parotitis has become much less common; this may reflect a change in the pattern of referrals. We recommend that the secretory IgA concentrations are estimated in cases of 'idiopathic' recurrent parotitis. Once the low IgA value is demonstrated, low dose antibiotic cover or prophylactic administration early in an attack is logical and advisable, if damage to the parotid is to be avoided.

JON LAWSON
149 Harley Street,
London W1 1HG

J R HOBBS
Department of Immunology,
Charing Cross and Westminster Medical School,
London SW1P 2AR


Paediatric outpatient utilisation in a district general hospital

EDITOR.—In their article on paediatric outpatient utilisation in a district general hospital,1 MacFaul and Long cited my own research in this field which was presented to the British Paediatric Association in 1989. My data included detailed information on the referral process and outcome in addition to utilisation data. Those wishing to compare the studies will find my results reported in full in Public Health.2

C M NI BHROLCHAIN
The Child Development Centre,
Northampton General Hospital,
Billing Road,
Northampton NN1 5BD


Kawasaki disease

EDITOR.—We would like to report the possibility of a Koebner phenomenon in Kawasaki disease.3 We recently admitted a 20 month old girl with a history of fever for 10 days, cervical lymphadenopathy, bulbar conjunctivitis, and dry fissured lips. She developed an erythematous, polymorphic eruption on the face, limbs, and trunk, and subsequently peeling of the finger tips.

This child had a plaster of Paris splint on the right leg from knee to toes as she was receiving treatment for talipes equinovarus. The child fulfilled the criteria for the diagnosis of Kawasaki disease and responded to intravenous immunoglobulin and aspirin treatment. During her stay in the ward her plaster was removed at the conclusion of her orthopaedic treatment and we were surprised to find no skin lesions beneath the plaster, though there were linear macular lesions at the edge of the cast where friction had occurred.

This finding suggests that the rash of Kawasaki disease acts as a Koebner or isomorphic phenomenon, with a tendency for the rash to develop at sites of skin trauma or friction. We are unaware of any previous report suggesting this mechanism.